Puma Biotechnology Reports Second Quarter 2026 Financial Results

$PBYIPress releaseAug 6, 2026, 4:05 PM ETRead the release

Puma Biotechnology reported Q2 2026 total revenue of $56.5 million, up from $52.4 million in the prior year, with net income reaching $8.2 million or $0.16 per share. Management raised full-year 2026 guidance, increasing net product revenue expectations to $205-209 million and total revenue to $224-231 million, citing increased demand for NERLYNX.

Key figures

Eps: 0.16
Revenue: $56.5 million
Guidance: Full Year 2026 Net Product Revenue $205-209 million, Total Revenue $224-231 million, Net Income $17-20 million
Rd expenses: $18.9 million
Gaap net income: $8.2 million
Net product revenue: $53.6 million
Non gaap net income: $10.1 million
Cash and equivalents: $93.9 million

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.